ClinicalTrials.gg
CompletedNCT00970632Updated Mar 12, 2012Results posted

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia

A Phase 3 interventional study of Tadalafil 5 mg and Placebo tablet in Benign Prostatic Hyperplasia (BPH), sponsored by Eli Lilly and Company. Completed at 44 sites in 10 countries. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2012-03-12.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
511
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.

Enrollment
7th of 26
511 · median 258
Started
2009
with 4 others
Phase 3
10 of 26
none open now
Registered
10th of 26
by date
Lead sponsor
16 of 26
Eli Lilly and Company

Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 7th largest by enrollment, is one of 5 that started in 2009, is one of 10 in phase 3, and was the 10th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tadalafil in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your bladder is still full etc.)

03

Conditions studied

  • Benign Prostatic Hyperplasia (BPH)

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men 45 years of age or older with benign prostatic hyperplasia (BPH) also referred to as BPH-lower urinary tract symptoms (LUTS) on the disease diagnostic criteria at the start of study.
  • Provide signed at the start of the study.
  • Agree not to use any other approved or experimental pharmacologic BPH, overactive bladder (OAB), or erectile dysfunction (ED) treatments anytime during the study.
  • Have not taken finasteride therapy for at least 3 months before study drug is dispensed and dutasteride therapy for at least 6 months before study drug is dispensed.
  • Have not taken other BPH therapy (including herbal preparations), OAB therapy, ED therapy for at least 4 weeks prior to study drug is dispensed.
  • Have LUTS with a total International Prostate Symptom Score (IPSS) greater than or equal to 13 when study drug is dispensed.
  • Have reduced urine flow (measured by special toilet equipment).
  • Demonstrate compliance with study drug administration requirements.

Exclusion criteria

Exclusion Criteria:

  • Treated with nitrates
  • Have unstable angina or angina that requires treatment.
  • Have had any of the following in the past 90 days: Heart attack, also known as a myocardial infarction (MI); Heart bypass surgery (called coronary artery bypass graft surgery); Had a procedure to open up blood vessels in the heart known as angioplasty or stent placement (percutaneous coronary intervention).
  • Have very high or very low blood pressure.
  • Have certain neurological conditions associated with bladder problems or injuries to brain or spinal cord within a specified time of starting this study.
  • Have uncontrolled diabetes.
  • Have prostate cancer, are being treated for cancer.
  • Have prostate specific antigen (PSA) greater than 10 nanograms per milliliter (ng/mL) at the start of study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
511 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo tablet with tamsulosin dose orally (po) once daily (QD) and placebo capsule with tadalafil dose po QD for 12 weeks

    Drug: Placebo tablet · Drug: Placebo capsule

  • Experimental
    Tadalafil 5 milligram (mg)

    Tadalafil 5 mg tablet po QD and placebo capsule po QD for 12 weeks

    Drug: Tadalafil 5 mg

  • Active comparator
    Tamsulosin 0.4 mg

    Tamsulosin 0.4 mg capsule po QD and placebo tablet po QD for 12 weeks

    Drug: Tamsulosin

Interventions

  • Tadalafil 5 mg po QD for 12 weeks

    Also known as: Cialis, LY450190

  • DrugPlacebo tablet

    Placebo tablet po QD for 12 weeks

  • Tamsulosin 0.4 mg po QD for 12 weeks

  • DrugPlacebo capsule

    Placebo capsule po QD for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total International Prostate Symptom Score (IPSS) at 12 Weeks

    The IPSS Total Score was obtained by combining the scores of the responses to Component Questions 1-7. Each question was scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represented greater severity of symptoms. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

    Time frame: Baseline, 12 weeks

Secondary outcomes

  1. Change From Baseline in Total International Prostate Symptom Score (IPSS) at 4 Weeks

    The IPSS Total Score was obtained by combining the scores of the responses to Component Questions 1-7. Each question was scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represented greater severity of symptoms. Least Squares (LS) Mean of change from baseline to endpoint (Week 4 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

    Time frame: Baseline, 4 weeks

  2. Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12 Weeks

    IPSS storage (irritative) subscore was the sum of Component Questions 2, 4 and 7 of the IPSS questionnaire. Scores ranged from 0 (no irritative symptoms) to 5 (frequent irritative symptoms); therefore, the 3 questions of the irritative subscore ranged from 0 to 15. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

    Time frame: Baseline, 12 weeks

  3. Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12 Weeks.

    IPSS voiding (obstructive) subscore was the sum of Component Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores ranged from 0 (no obstructive symptoms)-5 (frequent obstructive symptoms); therefore, the 4 questions of the obstructive score ranged from 0-20. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

    Time frame: Baseline, 12 weeks

  4. Change From Baseline in International Prostate Symptom Score (IPSS) Nocturia Question at 12 Weeks

    The IPSS nocturia question (Component Question 7) measured nocturia (need to urinate at night) over the past 4 weeks. Scores ranged from 0 (no episodes of nocturia)-5 (5 or more episodes of nocturia). Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

    Time frame: Baseline, 12 weeks

  5. Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index at 12 Weeks

    IPSS QoL assessed QoL by urinary symptoms, with scores ranging from 0 (delighted)-6 (terrible). Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

    Time frame: Baseline, 12 weeks

  6. Change From Baseline in Modified International Prostate Symptom Score (mIPSS) at 1 Week

    The mIPSS Total Score covered a time period of 1 week and was obtained by combining scores of responses to Component Questions 1-7. Each question was scored from 0-5 for an mIPSS range of 0-35 points; higher numerical scores represented greater severity of symptoms. Least Squares (LS) Mean of change from baseline to endpoint (Week 1 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

    Time frame: Baseline, 1 week

  7. Change From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 4 Weeks

    BII was a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores ranged from 0-13; higher scores represented increased perceived impact of BPH-lower urinary tract symptoms (LUTS) on overall health. Least Squares (LS) Mean of change from baseline to endpoint (Week 4 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

    Time frame: Baseline, 4 weeks

  8. Change From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 12 Weeks

    BII was a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores ranged from 0-13; higher scores represented increased perceived impact of BPH-lower urinary tract symptoms (LUTS) on overall health. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

    Time frame: Baseline, 12 weeks

  9. Patient Global Impression of Improvement (PGI-I) at 12 Weeks

    The PGI-I was a participant-rated instrument that measured the improvement or worsening of the participant's symptoms based on a 7-point scale at Week 12. A score of 1=participant felt symptoms were "very much better"; score of 2=participant felt symptoms were "much better"; score of 3=participant felt symptoms were "a little better"; score of 4=participant felt "no change" in symptoms; score of 5=participant felt symptoms were "a little worse"; score of 6=participant felt symptoms were "much worse"; score of 7=participant felt symptoms were "very much worse".

    Time frame: 12 weeks

  10. Clinician Global Impression of Improvement (CGI-I) at 12 Weeks

    The CGI-I was an investigator-rated instrument that measured improvement or worsening of the participant's symptoms based on a 7-point scale. A score of 1=participant felt symptoms were "very much better"; score of 2=participant felt symptoms were "much better"; score of 3=participant felt symptoms were "a little better"; score of 4=participant felt "no change" in symptoms; score of 5=participant felt symptoms were "a little worse"; score of 6=participant felt symptoms were "much worse"; score of 7=participant felt symptoms were "very much worse".

    Time frame: 12 weeks

  11. Treatment Satisfaction Scale - Benign Prostatic Hyperplasia (TSS-BPH) at 12 Weeks: Overall

    The TSS-BPH was a validated participant-rated instrument that measured participant satisfaction with treatment based on a 13-item questionnaire. The overall TSS-BPH score was converted to a percentage of the maximum value possible (percent ranged from 0-100) with lower scores indicating greater satisfaction.

    Time frame: 12 weeks

  12. Change From Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at 12 Weeks

    IIEF measured self-reported EF over the past 4 weeks. Scores ranged from 0 (low or no EF)-5 (high EF) on 6 questions (1-5, 15 of the IIEF). Total EF Domain scores ranged from 1-30. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

    Time frame: Baseline, 12 weeks

  13. Change From Baseline in Peak Urine Flow Rate (Q-Max) at 12 Weeks

    Q-max (peak urine flow rate) was measured in milliliters per second (mL/sec) using a standard calibrated flowmeter. At each visit, a uroflowmetry assessment was considered valid and data were included in the analyses only if the prevoid total bladder volume (assessed by ultrasound) was ≥150 to ≤550 mL and the voided volume (V-comp) was ≥125 mL.

    Time frame: Baseline, 12 weeks

  14. Change From Baseline in Mean Urine Flow Rate (Q-Mean) at 12 Weeks

    Q-mean (mean urine flow rate) was measured in milliliters per second (mL/sec) using a standard calibrated flowmeter. At each visit, a uroflowmetry assessment was considered valid and data were included in the analyses only if the prevoid total bladder volume (assessed by ultrasound) was ≥150 to ≤550 mL and the voided volume (V-comp) was \>=125 mL.

    Time frame: Baseline, 12 weeks

  15. Change From Baseline in Volume of Voided Urine (V-Comp) at 12 Weeks

    V-comp (volume of urine voided) was measured in milliliters (mL) using a standard calibrated flowmeter. At each visit, a uroflowmetry assessment was considered valid and data were included in the analyses only if the prevoid total bladder volume (assessed by ultrasound) was ≥150 to ≤550 mL and V-comp was ≥125 mL.

    Time frame: Baseline, 12 weeks

  16. Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks

    PVR was the amount of urine remaining in the bladder after void completion.

    Time frame: Baseline, 12 weeks

07

Results

Posted Dec 23, 2011

Participant flow

Participant flow — Overall Study
MilestonePlaceboTadalafil 5 mgTamsulosin 0.4 mg
Started172171168
Completed148156150
Not completed241518
Withdrew: Adverse event221
Withdrew: Lack of efficacy300
Withdrew: Lost to follow-up302
Withdrew: Protocol violation858
Withdrew: Withdrawal by subject764
Withdrew: Entry criteria not met022
Withdrew: Sponsor decision101

Outcome measures

PrimaryChange From Baseline in Total International Prostate Symptom Score (IPSS) at 12 Weeks

The IPSS Total Score was obtained by combining the scores of the responses to Component Questions 1-7. Each question was scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represented greater severity of symptoms. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Total International Prostate Symptom Score (IPSS) at 12 Weeks
units on a scalePlaceboTadalafil 5 mgTamsulosin 0.4 mg
Change From Baseline in Total International Prostate Symptom Score (IPSS) at 12 Weeks-4.2 ± 0.5-6.3 ± 0.5-5.7 ± 0.5
Statistical analysis
  • Placebo vs Tadalafil 5 mg · ANCOVA · p = 0.001 (The p-value associated with LS Mean difference of changes from baseline to Week 12 endpoint between tadalafil and placebo treatment groups was for the primary comparison and assessed for significance at a level of 0.05.) · Difference in ls means: -2.1
  • Placebo vs Tamsulosin 0.4 mg · ANCOVA · p = 0.023 (The p-value associated with LS Mean difference of changes from baseline to Week 12 between tamsulosin and placebo treatment groups was secondary in nature and assessed for significance at a level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: -1.5
SecondaryChange From Baseline in Total International Prostate Symptom Score (IPSS) at 4 Weeks

The IPSS Total Score was obtained by combining the scores of the responses to Component Questions 1-7. Each question was scored from 0-5 for an IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represented greater severity of symptoms. Least Squares (LS) Mean of change from baseline to endpoint (Week 4 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

Time frame:
Baseline, 4 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Total International Prostate Symptom Score (IPSS) at 4 Weeks
units on a scalePlaceboTadalafil 5 mgTamsulosin 0.4 mg
Change From Baseline in Total International Prostate Symptom Score (IPSS) at 4 Weeks-3.3 ± 0.4-5.5 ± 0.4-5.7 ± 0.4
Statistical analysis
  • Placebo vs Tadalafil 5 mg · ANCOVA · p = <0.001 (The p-value associated with LS Mean difference of changes from baseline to Week 4 between tadalafil and placebo treatment groups was assessed for significance at a level of 0.05.) · Difference in ls means: -2.2
  • Placebo vs Tamsulosin 0.4 mg · ANCOVA · p = <0.001 (The p-value associated with LS Mean difference of changes from baseline to Week 4 between tamsulosin and placebo treatment groups was assessed for significance at a level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: -2.3
SecondaryChange From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12 Weeks

IPSS storage (irritative) subscore was the sum of Component Questions 2, 4 and 7 of the IPSS questionnaire. Scores ranged from 0 (no irritative symptoms) to 5 (frequent irritative symptoms); therefore, the 3 questions of the irritative subscore ranged from 0 to 15. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12 Weeks
units on a scalePlaceboTadalafil 5 mgTamsulosin 0.4 mg
Change From Baseline in International Prostate Symptom Score (IPSS) Storage (Irritative) Subscore at 12 Weeks-1.6 ± 0.2-2.2 ± 0.2-2.2 ± 0.2
Statistical analysis
  • Placebo vs Tadalafil 5 mg · ANCOVA · p = 0.055 (The p-value associated with LS Mean difference of changes from baseline to Week 12 between tadalafil versus placebo treatment groups was assessed for significance at a level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: -0.6
  • Placebo vs Tamsulosin 0.4 mg · ANCOVA · p = 0.055 (The p-value associated with LS Mean difference of changes from baseline to Week 12 between tamsulosin versus placebo treatment groups was assessed for significance at a level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: -0.6
SecondaryChange From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12 Weeks.

IPSS voiding (obstructive) subscore was the sum of Component Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores ranged from 0 (no obstructive symptoms)-5 (frequent obstructive symptoms); therefore, the 4 questions of the obstructive score ranged from 0-20. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12 Weeks.
units on a scalePlaceboTadalafil 5 mgTamsulosin 0.4 mg
Change From Baseline in International Prostate Symptom Score (IPSS) Voiding (Obstructive) Subscore at 12 Weeks.-2.6 ± 0.3-4.1 ± 0.3-3.5 ± 0.3
Statistical analysis
  • Placebo vs Tadalafil 5 mg · ANCOVA · p = <0.001 (The p-value associated with LS Mean difference of changes from baseline to Week 12 between tadalafil versus placebo treatment groups was assessed for significance at a level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: -1.5
  • Placebo vs Tamsulosin 0.4 mg · ANCOVA · p = 0.026 (The p-value associated with LS Mean difference of changes from baseline to Week 12 between tamsulosin versus placebo treatment groups was assessed for significance at a level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: -1.0
SecondaryChange From Baseline in International Prostate Symptom Score (IPSS) Nocturia Question at 12 Weeks

The IPSS nocturia question (Component Question 7) measured nocturia (need to urinate at night) over the past 4 weeks. Scores ranged from 0 (no episodes of nocturia)-5 (5 or more episodes of nocturia). Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in International Prostate Symptom Score (IPSS) Nocturia Question at 12 Weeks
units on a scalePlaceboTadalafil 5 mgTamsulosin 0.4 mg
Change From Baseline in International Prostate Symptom Score (IPSS) Nocturia Question at 12 Weeks-0.3 ± 0.1-0.5 ± 0.1-0.5 ± 0.1
Statistical analysis
  • Placebo vs Tadalafil 5 mg · ANCOVA · p = 0.080 (The p-value associated with LS Mean difference of changes from baseline to Week 12 between tadalafil versus placebo treatment groups was assessed for significance at a level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: -0.2
  • Placebo vs Tamsulosin 0.4 mg · ANCOVA · p = 0.118 (The p-value associated with LS Mean difference of changes from baseline to Week 12 between tadalafil versus placebo treatment groups was assessed for significance at a level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: -0.2
SecondaryChange From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index at 12 Weeks

IPSS QoL assessed QoL by urinary symptoms, with scores ranging from 0 (delighted)-6 (terrible). Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index at 12 Weeks
units on a scalePlaceboTadalafil 5 mgTamsulosin 0.4 mg
Change From Baseline in International Prostate Symptom Score (IPSS) Quality of Life (QoL) Index at 12 Weeks-1.0 ± 0.1-1.3 ± 0.1-1.1 ± 0.1
Statistical analysis
  • Placebo vs Tadalafil 5 mg · ANCOVA · p = 0.022 (The p-value associated with LS Mean difference of changes from baseline to Week 12 between tadalafil versus placebo treatment groups was assessed for significance at a level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: -0.3
  • Placebo vs Tamsulosin 0.4 mg · ANCOVA · p = 0.546 (The p-value associated with LS Mean difference of changes from baseline to Week 12 endpoint between tamsulosin versus placebo treatment groups was assessed for significance at a level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: -0.1
SecondaryChange From Baseline in Modified International Prostate Symptom Score (mIPSS) at 1 Week

The mIPSS Total Score covered a time period of 1 week and was obtained by combining scores of responses to Component Questions 1-7. Each question was scored from 0-5 for an mIPSS range of 0-35 points; higher numerical scores represented greater severity of symptoms. Least Squares (LS) Mean of change from baseline to endpoint (Week 1 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

Time frame:
Baseline, 1 week
Reported as:
Least squares mean · units on a scale
Change From Baseline in Modified International Prostate Symptom Score (mIPSS) at 1 Week
units on a scalePlaceboTadalafil 5 mgTamsulosin 0.4 mg
Change From Baseline in Modified International Prostate Symptom Score (mIPSS) at 1 Week-2.5 ± 0.4-4.0 ± 0.4-4.0 ± 0.4
Statistical analysis
  • Placebo vs Tadalafil 5 mg · ANCOVA · p = 0.003 (The p-value associated with LS Mean difference of changes from baseline to Week 1 between tadalafil and placebo treatment groups was assessed for significance at a level of 0.05.) · Difference in ls means: -1.5
  • Placebo vs Tamsulosin 0.4 mg · ANCOVA · p = 0.005 (The p-value associated with LS Mean difference of changes from baseline to Week 1 between tamsulosin and placebo treatment groups was assessed for significance at a level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: -1.5
SecondaryChange From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 4 Weeks

BII was a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores ranged from 0-13; higher scores represented increased perceived impact of BPH-lower urinary tract symptoms (LUTS) on overall health. Least Squares (LS) Mean of change from baseline to endpoint (Week 4 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

Time frame:
Baseline, 4 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 4 Weeks
units on a scalePlaceboTadalafil 5 mgTamsulosin 0.4 mg
Change From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 4 Weeks-0.4 ± 0.2-1.2 ± 0.2-1.3 ± 0.2
Statistical analysis
  • Placebo vs Tadalafil 5 mg · ANCOVA · p = <0.001 (The p-value associated with LS Mean difference of changes from baseline to Week 4 between tadalafil and placebo treatment groups was assessed for significance at a level of 0.05.) · Difference in ls means: -0.8
  • Placebo vs Tamsulosin 0.4 mg · ANCOVA · p = <0.001 (The p-value associated with LS Mean difference of changes from baseline to Week 4 between tamsulosin and placebo treatment groups was assessed for significance at a level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: -0.9
SecondaryChange From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 12 Weeks

BII was a 4-item, self-administered questionnaire evaluating impact of urinary problems on overall health and activity. Total scores ranged from 0-13; higher scores represented increased perceived impact of BPH-lower urinary tract symptoms (LUTS) on overall health. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 12 Weeks
units on a scalePlaceboTadalafil 5 mgTamsulosin 0.4 mg
Change From Baseline in Benign Prostatic Hyperplasia Impact Index (BII) at 12 Weeks-0.9 ± 0.2-1.7 ± 0.2-1.5 ± 0.2
Statistical analysis
  • Placebo vs Tadalafil 5 mg · ANCOVA · p = 0.003 (The p-value associated with LS Mean difference of changes from baseline to Week 12 between tadalafil and placebo treatment groups was assessed for significance at a level of 0.05.) · Difference in ls means: -0.8
  • Placebo vs Tamsulosin 0.4 mg · ANCOVA · p = 0.026 (The p-value associated with LS Mean difference of changes from baseline to Week 12 endpoint between tamsulosin and placebo treatment groups was assessed for significance at a level of 0.05 with no adjustments for multiplicity.) · Difference in ls means: -0.6
SecondaryPatient Global Impression of Improvement (PGI-I) at 12 Weeks

The PGI-I was a participant-rated instrument that measured the improvement or worsening of the participant's symptoms based on a 7-point scale at Week 12. A score of 1=participant felt symptoms were "very much better"; score of 2=participant felt symptoms were "much better"; score of 3=participant felt symptoms were "a little better"; score of 4=participant felt "no change" in symptoms; score of 5=participant felt symptoms were "a little worse"; score of 6=participant felt symptoms were "much worse"; score of 7=participant felt symptoms were "very much worse".

Time frame:
12 weeks
Reported as:
Number · participants
Patient Global Impression of Improvement (PGI-I) at 12 Weeks
participantsPlaceboTadalafil 5 mgTamsulosin 0.4 mg
Very much worse200
Much worse210
A little worse468
No change512836
A little better535255
Much better365648
Very much better111710
Statistical analysis
  • Placebo vs Tadalafil 5 mg · Cochran-Mantel-Haenszel · p = 0.001 (The p-value associated with difference between tadalafil versus placebo treatment groups within the 7 response categories was assessed for significance at a level of 0.05 with no adjustment for multiplicity.)Analysis used data only from these treatment arms and stratification of baseline LUTS severity (moderate \[total IPSS \<20\]; severe \[total IPSS ≥20\]).
  • Placebo vs Tamsulosin 0.4 mg · Cochran-Mantel-Haenszel · p = 0.114 (The p-value associated with difference between tamsulosin versus placebo treatment groups within the 7 response categories was assessed for significance at a level of 0.05 with no adjustment for multiplicity.)Analysis used data only from these treatment arms and stratification of baseline LUTS severity (moderate \[total IPSS \<20\]; severe \[total IPSS ≥20\]).
SecondaryClinician Global Impression of Improvement (CGI-I) at 12 Weeks

The CGI-I was an investigator-rated instrument that measured improvement or worsening of the participant's symptoms based on a 7-point scale. A score of 1=participant felt symptoms were "very much better"; score of 2=participant felt symptoms were "much better"; score of 3=participant felt symptoms were "a little better"; score of 4=participant felt "no change" in symptoms; score of 5=participant felt symptoms were "a little worse"; score of 6=participant felt symptoms were "much worse"; score of 7=participant felt symptoms were "very much worse".

Time frame:
12 weeks
Reported as:
Number · participants
Clinician Global Impression of Improvement (CGI-I) at 12 Weeks
participantsPlaceboTadalafil 5 mgTamsulosin 0.4 mg
Very much worse100
Much worse221
A little worse657
No change513240
A little better575865
Much better345038
Very much better9166
Statistical analysis
  • Placebo vs Tadalafil 5 mg · Cochran-Mantel-Haenszel · p = 0.004 (The p-value associated with difference between tadalafil versus placebo treatment groups within the 7 response categories was assessed for significance at a level of 0.05 with no adjustment for multiplicity.)Analysis used data only from these treatment arms and a stratification of baseline LUTS severity (moderate \[total IPSS \<20\]; severe \[total IPSS ≥20\]).
  • Placebo vs Tamsulosin 0.4 mg · Cochran-Mantel-Haenszel · p = 0.452 (The p-value associated with difference between tamsulosin versus placebo treatment groups within the 7 response categories was assessed for significance at a level of 0.05 with no adjustment for multiplicity.)Analysis used data only from these treatment arms and stratification of baseline LUTS severity (moderate \[total IPSS \<20\]; severe \[total IPSS ≥20\]).
SecondaryTreatment Satisfaction Scale - Benign Prostatic Hyperplasia (TSS-BPH) at 12 Weeks: Overall

The TSS-BPH was a validated participant-rated instrument that measured participant satisfaction with treatment based on a 13-item questionnaire. The overall TSS-BPH score was converted to a percentage of the maximum value possible (percent ranged from 0-100) with lower scores indicating greater satisfaction.

Time frame:
12 weeks
Reported as:
Median · units on a scale
Treatment Satisfaction Scale - Benign Prostatic Hyperplasia (TSS-BPH) at 12 Weeks: Overall
units on a scalePlaceboTadalafil 5 mgTamsulosin 0.4 mg
Treatment Satisfaction Scale - Benign Prostatic Hyperplasia (TSS-BPH) at 12 Weeks: Overall28.9 ± 17.5022.2 ± 17.7428.9 ± 16.49
Statistical analysis
  • Placebo vs Tadalafil 5 mg · Van Elteren Tests · p = 0.005 (The p-value associated with the testing for differences in medians between tadalafil versus placebo treatment groups was assessed for significance at a level of 0.05 with no adjustment for multiplicity.) · Median of treatment group differences: -4.4P-values testing for differences of medians between placebo and active treatment were based on the Van Elteren test, stratifying by region.
  • Placebo vs Tamsulosin 0.4 mg · Van Elteren Tests · p = 0.457 (The p-value associated with the testing for differences in medians between tamsulosin versus placebo treatment groups was assessed for significance at a level of 0.05 without adjustments for multiplicity.) · Median of treatment group differences: -2.2P-values testing for differences of medians between placebo and active treatment were based on the Van Elteren test, stratifying by region.
SecondaryChange From Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at 12 Weeks

IIEF measured self-reported EF over the past 4 weeks. Scores ranged from 0 (low or no EF)-5 (high EF) on 6 questions (1-5, 15 of the IIEF). Total EF Domain scores ranged from 1-30. Least Squares (LS) Mean of change from baseline to endpoint (Week 12 or last post-baseline value carried forward) was from an analysis of covariance (ANCOVA) and adjusted for treatment group, region, centered-baseline covariate, centered-baseline-by-treatment interaction, and treatment-by-region interaction.

Time frame:
Baseline, 12 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at 12 Weeks
units on a scalePlaceboTadalafil 5 mgTamsulosin 0.4 mg
Change From Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at 12 Weeks2.1 ± 0.86.0 ± 0.81.7 ± 0.8
Statistical analysis
  • Placebo vs Tadalafil 5 mg · ANCOVA · p = <0.001 (The p-value associated with LS Mean difference of changes from baseline to Week 12 between tadalafil versus placebo treatment groups was assessed for significance at a level of 0.05 with no adjustment for multiplicity.) · Difference in ls means: 4.0
  • Placebo vs Tamsulosin 0.4 mg · ANCOVA · p = 0.699 (The p-value associated with LS Mean difference of changes from baseline to Week 12 between tamsulosin versus placebo treatment groups was assessed for significance at a level of 0.05 with no adjustment for multiplicity.) · Difference in ls means: -0.4
SecondaryChange From Baseline in Peak Urine Flow Rate (Q-Max) at 12 Weeks

Q-max (peak urine flow rate) was measured in milliliters per second (mL/sec) using a standard calibrated flowmeter. At each visit, a uroflowmetry assessment was considered valid and data were included in the analyses only if the prevoid total bladder volume (assessed by ultrasound) was ≥150 to ≤550 mL and the voided volume (V-comp) was ≥125 mL.

Time frame:
Baseline, 12 weeks
Reported as:
Median · milliliters per second (mL/sec)
Change From Baseline in Peak Urine Flow Rate (Q-Max) at 12 Weeks
milliliters per second (mL/sec)PlaceboTadalafil 5 mgTamsulosin 0.4 mg
Change From Baseline in Peak Urine Flow Rate (Q-Max) at 12 Weeks0.3 ± 4.841.6 ± 5.491.6 ± 4.06
Statistical analysis
  • Placebo vs Tadalafil 5 mg · ANOVA · p = 0.009 (The p-value associated with median difference of changes from baseline to Week 12 endpoint between tadalafil versus placebo treatment groups was assessed for significance at a level of 0.05 with no adjustment for multiplicity.)Analysis of variance (ANOVA) using rank transformed data.
  • Placebo vs Tamsulosin 0.4 mg · ANOVA · p = 0.014 (The p-value associated with median difference of changes from baseline to Week 12 endpoint between tamsulosin versus placebo treatment groups was assessed for significance at a level of 0.05 with no adjustment for multiplicity.)ANOVA using rank transformed data.
SecondaryChange From Baseline in Mean Urine Flow Rate (Q-Mean) at 12 Weeks

Q-mean (mean urine flow rate) was measured in milliliters per second (mL/sec) using a standard calibrated flowmeter. At each visit, a uroflowmetry assessment was considered valid and data were included in the analyses only if the prevoid total bladder volume (assessed by ultrasound) was ≥150 to ≤550 mL and the voided volume (V-comp) was \>=125 mL.

Time frame:
Baseline, 12 weeks
Reported as:
Median · milliliters per second (mL/sec)
Change From Baseline in Mean Urine Flow Rate (Q-Mean) at 12 Weeks
milliliters per second (mL/sec)PlaceboTadalafil 5 mgTamsulosin 0.4 mg
Change From Baseline in Mean Urine Flow Rate (Q-Mean) at 12 Weeks0.10 ± 2.721.25 ± 3.240.70 ± 3.03
SecondaryChange From Baseline in Volume of Voided Urine (V-Comp) at 12 Weeks

V-comp (volume of urine voided) was measured in milliliters (mL) using a standard calibrated flowmeter. At each visit, a uroflowmetry assessment was considered valid and data were included in the analyses only if the prevoid total bladder volume (assessed by ultrasound) was ≥150 to ≤550 mL and V-comp was ≥125 mL.

Time frame:
Baseline, 12 weeks
Reported as:
Median · milliliter (mL)
Change From Baseline in Volume of Voided Urine (V-Comp) at 12 Weeks
milliliter (mL)PlaceboTadalafil 5 mgTamsulosin 0.4 mg
Change From Baseline in Volume of Voided Urine (V-Comp) at 12 Weeks0.0 ± 110.9211.0 ± 101.4516.0 ± 109.30
SecondaryChange From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks

PVR was the amount of urine remaining in the bladder after void completion.

Time frame:
Baseline, 12 weeks
Reported as:
Median · milliliter (mL)
Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks
milliliter (mL)PlaceboTadalafil 5 mgTamsulosin 0.4 mg
Change From Baseline in Postvoid Residual Volume (PVR) at 12 Weeks0.0 ± 56.48-1.0 ± 46.97-5.5 ± 59.21
Statistical analysis
  • Placebo vs Tadalafil 5 mg · ANOVA · p = 0.303 (The p-value associated with median difference of changes from baseline to Week 12 endpoint between tadalafil versus placebo treatment groups was assessed for significance at a level of 0.05 with no adjustment for multiplicity.)Analysis of variance (ANOVA) using rank transformed data.
  • Placebo vs Tamsulosin 0.4 mg · ANOVA · p = 0.146 (The p-value associated with median difference of changes from baseline to Week 12 endpoint between tamsulosin versus placebo treatment groups was assessed for significance at a level of 0.05 with no adjustment for multiplicity.)ANOVA using rank transformed data.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tadalafil 5 mg—2/171 (1.2%)39/171 (22.8%)
Tamsulosin 0.4 mg—2/168 (1.2%)40/168 (23.8%)
Placebo—0/172 (0%)35/172 (20.3%)
Most frequent serious events
Most frequent serious events
EventTadalafil 5 mgTamsulosin 0.4 mgPlacebo
TachycardiaCardiac disorders0/1711/1680/172
DyspepsiaGastrointestinal disorders0/1711/1680/172
DizzinessNervous system disorders0/1711/1680/172
HeadacheNervous system disorders0/1711/1680/172
HyperhidrosisSkin and subcutaneous tissue disorders0/1711/1680/172
FlushingVascular disorders0/1711/1680/172
Coronary artery diseaseCardiac disorders1/1710/1680/172
PancreatitisGastrointestinal disorders1/1710/1680/172
Most frequent other events
Showing 10 of 95
Most frequent other events
EventTadalafil 5 mgTamsulosin 0.4 mgPlacebo
NasopharyngitisInfections and infestations5/1713/1688/172
HeadacheNervous system disorders5/1716/1682/172
DizzinessNervous system disorders4/1715/1683/172
DyspepsiaGastrointestinal disorders4/1712/1680/172
Back painMusculoskeletal and connective tissue disorders4/1712/1681/172
CoughRespiratory, thoracic and mediastinal disorders2/1713/1681/172
Gastrooesophageal reflux diseaseGastrointestinal disorders3/1710/1680/172
Pain in extremityMusculoskeletal and connective tissue disorders3/1711/1680/172
FlushingVascular disorders3/1711/1680/172
NauseaGastrointestinal disorders1/1711/1683/172

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboTadalafil 5 mgTamsulosin 0.4 mgTotal
Mean63.7 ± 8.6563.5 ± 8.0863.5 ± 7.7663.6 ± 8.16
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTadalafil 5 mgTamsulosin 0.4 mgTotal
Female0000
Male172171168511
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboTadalafil 5 mgTamsulosin 0.4 mgTotal
Hispanic or Latino494743139
Not Hispanic or Latino123124125372
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboTadalafil 5 mgTamsulosin 0.4 mgTotal
American Indian or Alaska Native414037118
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0101
White131130131392
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)PlaceboTadalafil 5 mgTamsulosin 0.4 mgTotal
Australia691025
Austria1310730
Belgium56718
France991230
Germany565056162
Greece84719
Italy18261559
Mexico434138122
Netherlands23611
Poland12131035
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))PlaceboTadalafil 5 mgTamsulosin 0.4 mgTotal
Mean28.1 ± 4.0927.1 ± 4.0327.9 ± 3.7327.7 ± 3.96
Lower Urinary Tract Symptom (LUTS) Severity
Lower Urinary Tract Symptom (LUTS) Severity(participants)PlaceboTadalafil 5 mgTamsulosin 0.4 mgTotal
Moderate (IPSS <20)118123119360
Severe (IPSS ≥20)544849151
Peak Urine Flow Rate (Qmax) Category
Peak Urine Flow Rate (Qmax) Category(participants)PlaceboTadalafil 5 mgTamsulosin 0.4 mgTotal
<10 mL/sec7992105276
10-15 mL/sec696353185
>15 mL/sec1812737

7 further baseline measures are reported on the registry.

08

Study locations

44 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Adelaide, South Australia 5000, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bentleigh East, Victoria 3165, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bunbury, Western Australia 6230, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nedlands, Western Australia 6009, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salzburg, 5020, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vienna, 1220, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brussels, 1070, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gent, 9000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Liege, 4000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Garches, 92380, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nice, 06002, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orleans, 45067, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75475, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pierre Benite, 69495, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Suresnes, 92150, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bad Rappenau, 74906, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bad Wiessee, D-83707, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hannover, 30625, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leipzig, 04109, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marburg, 35039, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Muehlacker, D-75417, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oranienburg, D-16515, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Heraklion, 71110, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ioannina, 45500, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Larissa, 41221, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Patras, 26500, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Thessaloniki, 56429, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bergamo, 24128, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cagliari, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Firenze, 50139, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Napoli, 80131, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sassari, 07100, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64710, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Morelia, 58000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saltillo, 25210, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zapopan, 45070, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Arnhem, 6803 AA, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Breda, 4819 EV, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    S-Hertogenbosch, 5211 NL, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tilburg, 5022 GC, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Veldhoven, 5504 DB, Netherlands
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bialystok, 15-276, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kutno, 99-300, Poland
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Warsaw, 02-005, Poland
09

References and documents

Publications

  • Vlachopoulos C, Oelke M, Maggi M, Mulhall JP, Rosenberg MT, Brock GB, Esler A, Buttner H. Impact of cardiovascular risk factors and related comorbid conditions and medical therapy reported at baseline on the treatment response to tadalafil 5 mg once-daily in men with lower urinary tract symptoms associated with benign prostatic hyperplasia: an integrated analysis of four randomised, double-blind, placebo-controlled, clinical trials. Int J Clin Pract. 2015 Dec;69(12):1496-507. doi: 10.1111/ijcp.12722. Epub 2015 Aug 24. PubMed 26299520 ↗
  • Giuliano F, Oelke M, Jungwirth A, Hatzimouratidis K, Watts S, Cox D, Viktrup L. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo- and tamsulosin-controlled, 12-week double-blind study. J Sex Med. 2013 Mar;10(3):857-65. doi: 10.1111/jsm.12039. Epub 2013 Jan 24. PubMed 23346990 ↗
  • Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012 May;61(5):917-25. doi: 10.1016/j.eururo.2012.01.013. Epub 2012 Jan 20. PubMed 22297243 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2009
First posted
Sep 2, 2009
Start
Oct 2009
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Results first posted
Dec 23, 2011
Last update
Mar 12, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00970632
Responsible party
Sponsor
First posted
Sep 2, 2009
Start date
Oct 2009
Primary completion
Jan 2011
Completion
Jan 2011
Results posted
Dec 23, 2011
Last update
Mar 12, 2012

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion